Purpose
|
A vasodilator used in angina of effort or ischemic heart disease. rimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of fatty acid metabolism, also known as fatty acid oxidation inhibitor.
|
Characteristics
|
Tradename: Trimetazidine dihydrochloride Source of Compound: synthetic, 400045 Receptor: LCKT(β-oxidation) Status: INN, BAN, JAN
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
98?%
|
Formula
|
C14H22N2O3.2HCl
|
Solubility
|
10 mM in H2O
|